XML 71 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Caelum Biosciences (Tables)
3 Months Ended
Mar. 31, 2021
Noncontrolling Interest [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed The following table summarizes the assets acquired and liabilities assumed in connection with the consolidation of Caelum:
Assets Acquired and Liabilities Assumed
Cash and cash equivalents$16.9 
Acquired in-process research and development193.3 
Other assets and liabilities, net6.8 
Total net assets acquired$217.0 
Schedule of Variable Interest Entities The carrying value of the assets and liabilities associated with Caelum included in the condensed consolidated balance sheets as of March 31, 2021, which are limited in use for its operations and do not have recourse against our general credit are as follows:
March 31, 2021
Cash and cash equivalents$56.5 
Prepaid expenses and other current assets$8.6 
Other assets$7.8 
Accounts payable$3.6 
Accrued expenses$2.3